Download PDF
Exp Clin Endocrinol Diabetes 2021; 129(03): 203-207
DOI: 10.1055/a-1197-6380
Review

Mortality of Patients with Cushing’s Disease

Georgia Ntali
1   Department of Endocrinology, Diabetes and Metabolism, Evangelismos Hospital, Athens, Greece
,
Osamah Hakami
2   Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom of Great Britain and Northern Ireland
3   Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, United Kingdom of Great Britain and Northern Ireland
4   Department of Endocrinology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom of Great Britain and Northern Ireland
,
Milanka Wattegama
2   Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom of Great Britain and Northern Ireland
3   Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, United Kingdom of Great Britain and Northern Ireland
4   Department of Endocrinology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom of Great Britain and Northern Ireland
,
Shahzada Ahmed
5   Department of Ear, Nose & Throat, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom of Great Britain and Northern Ireland
,
Niki Karavitaki
2   Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom of Great Britain and Northern Ireland
3   Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, United Kingdom of Great Britain and Northern Ireland
4   Department of Endocrinology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom of Great Britain and Northern Ireland
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Cushing’s disease is a rare condition of cortisol excess attributed to a pituitary adenoma with an annual incidence of 1.2–2.4 cases per million population. It is associated with several co-morbidities leading to increased mortality predominantly due to cardiovascular disease. Despite the advances in its diagnosis and management, survival can be compromised even after apparent successful treatment. Minimizing the duration and extent of exposure to hypercortisolaemia by early diagnosis and rapid, effective therapeutic interventions, as well as close monitoring and aggressive control of cardiovascular risk factors are vital for improving outcomes of the patients.

Key words

Cushing’s disease - cortisol excess - mortality - survival - remission - cardiovascular risk


Publication History

Received: 29 April 2020
Received: 02 June 2020

Accepted: 09 June 2020

Article published online:
09 July 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Etxabe J, Vazquez JA. Morbidity and mortality in Cushing’s disease: An epidemiological approach. Clin Endocrinol 1994; 40: 479-484
    CrossrefPubMedGoogle Scholar
  • 2 Wengander S, Trimpou P, Papakokkinou E. et al. The incidence of endogenous Cushing’s syndrome in the modern era. Clin Endocrinol 2019; 91: 263-270
    CrossrefPubMedGoogle Scholar
  • 3 Lindholm J, Juul S, Jørgensen JO. et al. Incidence and late prognosis of Cushing’s syndrome: A population-based study. J Clin Endocrinol Metab 2001; 86: 117-123
    PubMedGoogle Scholar
  • 4 Bolland MJ, Holdaway IM, Berkeley JE. et al. Mortality and morbidity in Cushing’s syndrome in New Zealand. Clin Endocrinol 2011; 75: 436-442
    CrossrefPubMedGoogle Scholar
  • 5 Ragnarsson O, Olsson DS, Chantzichristos D. et al. The incidence of Cushing’s disease: A nationwide Swedish study. Pituitary 2019; 22: 179-186
    CrossrefPubMedGoogle Scholar
  • 6 Agustsson TT, Baldvinsdottir T, Jonasson JG. et al. The epidemiology of pituitary adenomas in Iceland, 1955-2012: A nationwide population-based study. Eur J Endocrinol 2015; 173: 655-664
    CrossrefPubMedGoogle Scholar
  • 7 Tjörnstrand A, Gunnarsson K, Evert M. et al. The incidence rate of pituitary adenomas in western Sweden for the period 2001-2011. Eur J Endocrinol 2014; 171: 519-526
    CrossrefPubMedGoogle Scholar
  • 8 Day PF, Loto MG, Glerean M. et al. Incidence and prevalence of clinically relevant pituitary adenomas: Retrospective cohort study in a Health Management Organization in Buenos Aires, Argentina. Arch Endocrinol Metab 2016; 60: 554-561
    CrossrefPubMedGoogle Scholar
  • 9 Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: A community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol 2010; 72: 377-382
    CrossrefPubMedGoogle Scholar
  • 10 Daly AF, Rixhon M, Adam C. et al. High prevalence of pituitary adenomas: A cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 2006; 91: 4769-4775
    CrossrefPubMedGoogle Scholar
  • 11 Ntali G, Asimakopoulou A, Siamatras T. et al. Mortality in Cushing’s syndrome: Systematic analysis of a large series with prolonged follow-up. Eur J Endocrinol 2013; 169: 715-723
    CrossrefPubMedGoogle Scholar
  • 12 Hassan-Smith ZK, Sherlock M, Reulen RC. et al. Outcome of Cushing’s disease following transsphenoidal surgery in a single center over 20 years. J Clin Endocrinol Metab 2012; 97: 1194-1201
    CrossrefPubMedGoogle Scholar
  • 13 Clayton RN, Raskauskiene D, Reulen RC. et al. Mortality and morbidity in Cushing’s disease over 50 years in Stoke-on-Trent, UK: Audit and meta-analysis of literature. J Clin Endocrinol Metab 2011; 96: 632-642
    CrossrefPubMedGoogle Scholar
  • 14 Clayton RN, Jones PW, Reulen RC. et al. Mortality in patients with Cushing’s disease more than 10 years after remission: A multicentre, multinational, retrospective cohort study. Lancet Diabetes Endocrinol 2016; 4: 569-576
    CrossrefPubMedGoogle Scholar
  • 15 Dekkers OM, Biermasz NR, Pereira AM. et al. Mortality in patients treated for Cushing’s disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 2007; 92: 976-981
    CrossrefPubMedGoogle Scholar
  • 16 Geer EB, Shafiq I, Gordon MB. et al. Biochemical control during long-term follow up of 230 adult patients with Cushing disease: A multicenter retrospective study. Endocr Pract 2017; 23: 962-970
    CrossrefPubMedGoogle Scholar
  • 17 Hammer GD, Tyrrell JB, Lamborn KR. et al. Transsphenoidal microsurgery for Cushing’s disease: Initial outcome and long-term results. J Clin Endocrinol Metab 2004; 89: 6348-6357
    CrossrefPubMedGoogle Scholar
  • 18 Lambert JK, Goldberg L, Fayngold S. et al. Predictors of mortality and long-term outcomes in treated Cushing’s disease: A study of 346 patients. J Clin Endocrinol Metab 2013; 98: 1022-1030
    CrossrefPubMedGoogle Scholar
  • 19 Ragnarsson O, Olsson DS, Papakokkinou E. et al. Overall and disease-specific mortality in patients with cushing disease: A Swedish Nationwide Study. J Clin Endocrinol Metab 2019; 104: 2375-2384
    CrossrefPubMedGoogle Scholar
  • 20 Yaneva M, Kalinov K, Zacharieva S. Mortality in Cushing’s syndrome: data from 386 patients from a single tertiary referral center. Eur J Endocrinol 2013; 169: 621-627
    CrossrefPubMedGoogle Scholar
  • 21 Valassi E, Santos A, Yaneva M. et al. ERCUSYN Study Group. The European Registry on Cushing’s syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol 2011; 165: 383-392
    CrossrefPubMedGoogle Scholar
  • 22 Dekkers OM, Horváth-Puhó E, Jørgensen JO. et al. Multisystem morbidity and mortality in Cushing’s syndrome: a cohort study. J Clin Endocrinol Metab 2013; 98: 2277-2284
    CrossrefPubMedGoogle Scholar
  • 23 Ntali G, Grossman A, Karavitaki N. Clinical and biochemical manifestations of Cushing’s. Pituitary 2015; 18: 181-187
    CrossrefPubMedGoogle Scholar
  • 24 Broersen LHA, Andela CD, Dekkers OM. et al. Improvement but no normalization of quality of life and cognitive functioning after treatment of Cushing syndrome. J Clin Endocrinol Metab 2019; 104: 5325-5337
    PubMedGoogle Scholar
  • 25 Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull Johns Hopkins Hosp 1932; 50: 137
    PubMedGoogle Scholar
  • 26 Plotz CM, Knowlton AI, Ragan C. The natural history of Cushing’s syndrome. Am J Med 1952; 13: 597-614
    CrossrefPubMedGoogle Scholar
  • 27 Pikkarainen L, Sane T, Reunanen A. The survival and wellbeing of patients treated for Cushing’s syndrome. Journal of Internal Medicine 1999; 245: 463-468
    CrossrefPubMedGoogle Scholar
  • 28 Swearingen B, Biller BM, Barker FG. et al. Long-term mortality after transsphenoidal surgery for Cushing’s disease. Annals of Internal Medicine 1999; 130: 821-824
    CrossrefPubMedGoogle Scholar
  • 29 Colao A, Pivonello R, Spiezia S. et al. Persistence of increased cardiovascular risk in patients with Cushing’s disease after five years of successful cure. J Clin Endocrinol Metab 1999; 84: 2664-2672
    PubMedGoogle Scholar
  • 30 Barahona MJ, Sucunza N, Resmini E. et al. Persistent body fat mass and inflammatory marker increases after long-term cure of Cushing’s syndrome. J Clin Endocrinol Metab 2009; 94: 3365-3371
    CrossrefPubMedGoogle Scholar
  • 31 Faggiano A, Pivonello R, Spiezia S. et al. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing’s disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 2003; 88: 2527-2533
    CrossrefPubMedGoogle Scholar
  • 32 Andela CD, van der Werff SJ, Pannekoek JN. et al. Smaller grey matter volumes in the anterior cingulate cortex and greater cerebellar volumes in patients with long-term remission of Cushing’s disease: A case-control study. Eur J Endocrinol 2013; 169: 811-819
    CrossrefPubMedGoogle Scholar